Independent Research set a €97.00 ($119.75) price objective on MorphoSys (ETR:MOR) in a research report sent to investors on Tuesday morning. The firm currently has a buy rating on the stock.

A number of other equities analysts have also recently issued reports on MOR. Goldman Sachs Group set a €80.00 ($98.77) target price on MorphoSys and gave the stock a neutral rating in a report on Monday, November 27th. Berenberg Bank set a €85.00 ($104.94) price target on MorphoSys and gave the company a buy rating in a report on Thursday, December 7th. JPMorgan Chase & Co. set a €86.00 ($106.17) price target on MorphoSys and gave the company a buy rating in a report on Tuesday, December 12th. HSBC set a €64.00 ($79.01) price target on MorphoSys and gave the company a sell rating in a report on Friday, January 19th. Finally, Royal Bank of Canada set a €57.00 ($70.37) price target on MorphoSys and gave the company a sell rating in a report on Wednesday, February 14th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. MorphoSys has an average rating of Hold and a consensus price target of €83.00 ($102.47).

How to Become a New Pot Stock Millionaire

MorphoSys (ETR:MOR) opened at €87.25 ($107.72) on Tuesday. The stock has a market capitalization of $2,550.00 and a price-to-earnings ratio of -29.58. MorphoSys has a 1-year low of €49.63 ($61.27) and a 1-year high of €87.40 ($107.90).

TRADEMARK VIOLATION WARNING: This piece was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.dailypolitical.com/2018/03/14/independent-research-analysts-give-morphosys-mor-a-97-00-price-target.html.

About MorphoSys

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.